Rep. Lisa C. McClain Buys Baxter International Inc. (NYSE:BAX) Stock

Representative Lisa C. McClain (R-Michigan) recently bought shares of Baxter International Inc. (NYSE:BAX). In a filing disclosed on November 21st, the Representative disclosed that they had bought between $1,001 and $15,000 in Baxter International stock on October 30th. The trade occurred in the Representative’s “CHARLES SCHWAB 401K > SCHWAB 893” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Coherent (NYSE:COHR) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Clorox (NYSE:CLX) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Northern Trust (NASDAQ:NTRS) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Honda Motor (NYSE:HMC) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Home BancShares (NYSE:HOMB) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Five Below (NASDAQ:FIVE) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Pure Storage (NYSE:PSTG) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of BHP Group (NYSE:BHP) on 10/31/2025.

Baxter International Price Performance

NYSE:BAX traded up $0.48 on Tuesday, reaching $18.66. The stock had a trading volume of 7,325,389 shares, compared to its average volume of 5,884,267. The company has a quick ratio of 1.49, a current ratio of 2.30 and a debt-to-equity ratio of 1.30. The company has a market capitalization of $9.59 billion, a P/E ratio of -62.21, a price-to-earnings-growth ratio of 0.73 and a beta of 0.57. Baxter International Inc. has a 1-year low of $17.40 and a 1-year high of $37.74. The stock has a fifty day moving average price of $21.07 and a 200-day moving average price of $25.40.

Baxter International (NYSE:BAX) last posted its earnings results on Thursday, October 30th. The medical instruments supplier reported $0.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.60 by $0.09. The company had revenue of $2.84 billion during the quarter, compared to analysts’ expectations of $2.88 billion. Baxter International had a negative net margin of 1.42% and a positive return on equity of 16.96%. Baxter International’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.80 earnings per share. Baxter International has set its Q4 2025 guidance at 0.520-0.570 EPS. FY 2025 guidance at 2.350-2.400 EPS. Research analysts forecast that Baxter International Inc. will post 2.48 EPS for the current year.

Baxter International Cuts Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 2nd. Investors of record on Friday, November 28th will be issued a dividend of $0.01 per share. This represents a $0.04 annualized dividend and a yield of 0.2%. The ex-dividend date of this dividend is Friday, November 28th. Baxter International’s dividend payout ratio (DPR) is currently -6.06%.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Wall Street Zen lowered Baxter International from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. Citigroup lowered their price target on shares of Baxter International from $26.00 to $21.00 and set a “neutral” rating for the company in a research report on Friday, October 31st. Cowen restated a “hold” rating on shares of Baxter International in a report on Thursday, October 30th. UBS Group lowered their target price on shares of Baxter International from $24.00 to $21.00 and set a “neutral” rating for the company in a report on Friday, October 31st. Finally, JPMorgan Chase & Co. cut their price target on Baxter International from $25.00 to $19.00 in a research note on Friday, October 31st. Two research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Reduce” and an average price target of $23.70.

Institutional Investors Weigh In On Baxter International

Several hedge funds have recently bought and sold shares of the company. Greenhaven Associates Inc. acquired a new position in shares of Baxter International in the 3rd quarter valued at $143,186,000. Dodge & Cox lifted its holdings in shares of Baxter International by 10.1% during the 3rd quarter. Dodge & Cox now owns 57,396,370 shares of the medical instruments supplier’s stock valued at $1,306,915,000 after purchasing an additional 5,274,750 shares in the last quarter. Russell Investments Group Ltd. grew its position in shares of Baxter International by 32.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 2,515,928 shares of the medical instruments supplier’s stock valued at $57,243,000 after purchasing an additional 615,100 shares during the period. Cooke & Bieler LP increased its stake in Baxter International by 25.7% during the 3rd quarter. Cooke & Bieler LP now owns 2,200,860 shares of the medical instruments supplier’s stock worth $50,114,000 after purchasing an additional 450,350 shares in the last quarter. Finally, Sound Shore Management Inc. CT raised its holdings in Baxter International by 13.7% during the 1st quarter. Sound Shore Management Inc. CT now owns 2,825,902 shares of the medical instruments supplier’s stock worth $96,731,000 after buying an additional 341,321 shares during the period. 90.19% of the stock is currently owned by institutional investors and hedge funds.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.